Clin Psychopharmacol Neurosci.  2014 Apr;12(1):19-30.

Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder

Affiliations
  • 1Department of Psychiatry, Kyung Hee University School of Medicine, Seoul, Korea. mompeian@khu.ac.kr
  • 2Department of Life Sciences, Ewha Womans University, Seoul, Korea.
  • 3Kyung Hee University School of Medicine, Seoul, Korea.
  • 4Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea.
  • 5Department of Pharmacology, Konkuk University School of Medicine, Seoul, Korea.
  • 6Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea.
  • 7Department of Psychiatry, Dankook University Medical College, Chungnam, Korea.

Abstract

In clinical practice, pharmacological treatment is mostly focused on behavioral symptoms in everyday life. Nevertheless, persistent effort continues to develop medication for causal treatment. Recent changes in diagnostic criteria from Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) to DSM-5 would affect not only diagnosing approaches, but also therapeutic approaches. Because previous pervasive developmental disorders have been integrated into a single entity, the autism spectrum disorder (ASD), we have to prepare for what medications are valuable for the ASD. In this article, we reviewed the following etiological treatment: acetylcholine and glutamate related medicine; amino acid medicine such as secretin, endogenous opioid, and oxytocin; complementary and alternative medicine such as chelating agents, vitamins, and omega-3; promising drugs related to the scope of pharmacogenetics currently under study.

Keyword

Child development disorders, pervasive; Drug therapy; Etiology
Full Text Links
  • CPN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr